B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?
Marcin P MyckoPublished in: Neurologia i neurochirurgia polska (2020)
The current pandemic highlights the need to develop more selective and safer methods of immunomodulation in MS. B cells represent several functionally different populations. Further research into the different role of these cells during autoimmune demyelination should yield better, safer strategies to control the encephalitogenic process.
Keyphrases
- sars cov
- multiple sclerosis
- coronavirus disease
- end stage renal disease
- mass spectrometry
- respiratory syndrome coronavirus
- ms ms
- newly diagnosed
- induced apoptosis
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cancer therapy
- cell cycle arrest
- drug delivery
- patient reported outcomes
- genetic diversity
- pi k akt